# Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

> **NCT03615105** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Acute Lymphoid Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **RADIATION:** Hyperfractionated total body irradiation
- **DRUG:** Thiotepa
- **DRUG:** Cyclophosphamide
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Clofarabine
- **PROCEDURE:** HPC(A) stem cell allograft
- **DRUG:** Rituximab
- **DEVICE:** Rabbit antithymocyte globulin

## Key facts

- **NCT ID:** NCT03615105
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-25
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-03-06
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615105, "Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03615105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*